Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

633
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same author

Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.

Urologic oncology·2026
Same author

Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohort.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Re: Kitamura et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection (JCOG1019). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008.

European urology·2026
Same author

Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Noninvasive Differentiation of Indolent from Aggressive Renal Neoplasms with MR Fingerprinting Combined with Diffusion/Perfusion MRI.

Radiology·2026

Related Experiment Video

Updated: Jan 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A

Nicholas G Zaorsky1, Yilun Sun1, Abdenour Nabid2

  • 1Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve School of Medicine, Cleveland, Ohio.

JAMA Oncology
|November 20, 2025
PubMed
Summary
This summary is machine-generated.

Determining the ideal duration of androgen deprivation therapy (ADT) for prostate cancer is crucial. This meta-analysis found benefits up to 9-12 months, with increased risks beyond that, guiding personalized treatment.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

647
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.9K

Related Experiment Videos

Last Updated: Jan 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

647
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.9K

Area of Science:

  • Oncology
  • Radiotherapy
  • Prostate Cancer Treatment

Background:

  • The optimal duration of androgen deprivation therapy (ADT) for localized prostate cancer remains unclear.
  • Clinical trials have used variable ADT durations, complicating treatment guidelines.

Purpose of the Study:

  • To determine the ideal duration of ADT for patients with prostate cancer treated with radiotherapy.
  • To provide individualized risk estimates for ADT duration based on patient risk factors.

Main Methods:

  • Individual patient data meta-analysis of 13 randomized phase 3 clinical trials.
  • Systematic literature search from 1980-2020 across multiple databases.
  • Analysis included 10,266 male patients with a median follow-up of 11.3 years.

Main Results:

  • Longer ADT durations showed nonlinear improvements in distant metastasis and survival, with diminishing returns beyond 9-12 months.
  • A near-linear increase in other-cause mortality was observed with long-term ADT use.
  • Optimal ADT duration varied by risk group, ranging from 0 to 12 months or undefined for high-risk disease.

Conclusions:

  • Increasing ADT duration offers relative and absolute benefits for localized prostate cancer patients treated with radiotherapy.
  • Findings support individualized ADT duration recommendations based on risk stratification.
  • Careful consideration of benefits versus risks, including other-cause mortality, is essential for long-term ADT.